Literature DB >> 25852204

Improving Diabetes Care for Hospice Patients.

Sei J Lee1, Margaret A Jacobson2, C Bree Johnston3.   

Abstract

Although type 2 diabetes guidelines recommend less aggressive glycemic control for patients with limited life expectancy, many hospice patients continue their glucose-lowering medications, resulting in an increased risk of hypoglycemia. Three common reasons for overly tight glycemic control in hospice patients include (1) discussions about reducing or stopping chronic medications are uncomfortable; (2) many patients and families believe that mild hyperglycemia can cause symptoms; and (3) until 2014, Healthcare Information and Data Information Set (HEDIS) quality indicators for glycemic control included hospice patients. To address these issues, we recommend (1) providers discuss with patients and families upon hospice enrollment that diabetes medications can be reduced or discontinued as their life-limiting disease progresses; (2) keeping blood glucose levels between 200 and 300 mg/dL; and (3) educate providers that HEDIS measures now exclude hospice patients. Implementing these recommendations should decrease the risk of hypoglycemia in hospice patients and improve their quality of life.
© The Author(s) 2015.

Entities:  

Keywords:  diabetes mellitus; glucose lowering medication; glycemic control; hospice; hyperglycemia; hypoglycemia

Mesh:

Substances:

Year:  2015        PMID: 25852204     DOI: 10.1177/1049909115578386

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  2 in total

1.  Inpatient Hospices in Germany: Medical Care Situation and Use of Supportive Oncological Therapies for Symptom Control in Tumor Patients.

Authors:  Ulrich Kaiser; Ursula Vehling-Kaiser; Ana Hoffmann; Florian Kaiser
Journal:  Palliat Med Rep       Date:  2022-08-18

2.  Respecting Autonomy and Promoting the Patient's Good in the Setting of Serious Terminal and Concurrent Mental Illness.

Authors:  Kathleen M McKillip; Amy D Lott; Keith M Swetz
Journal:  Yale J Biol Med       Date:  2019-12-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.